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ess: b.arroll@auckland.Summary Objectives: The aim of this paper is to review the four Cochrane reviews
of antibiotics for upper respiratory tract infections.
Methods: Each Cochrane review was read and summarized, and results presented
as odds ratios (as in the Internet version) and, where relevant, numbers needed to
treat.
Results: The reviews of antibiotics for acute otitis media have concluded that
benefit is not great with a number needed to treat for a benefit (NNTB) of 15. Recent
US guidelines are recommending a delay in prescriptions in children over the age of 6
months. For streptococcal tonsillitis, the Cochrane reviewers suggest that antibiotic
use seems to be discretionary rather than prohibited or mandatory. This is because
the benefit in terms of symptoms is only about 16 h (NNTB from 2 to 7 at day 3 for
pain) compared with placebo, and that serious complications, such as rheumatic
fever and glomerulonephritis, are now rare in developed countries. The reviewers
do, however, suggest that antibiotics are considered in populations in whom these
complications are more common. This is an area of debate, as the Infectious Disease
Society of America (2002) recommends routine treatment. [Clin. Infect. Dis. 35
(2002) 113] There is good evidence and consensus that there is no indication for
antibiotics for the common cold. The situation with acute purulent rhinitis is less
clear, as new evidence suggests that antibiotics may be effective for acute purulent
rhinitis (NNTB from 6 to 8). However, as most people with acute purulent rhinitis
improve without antibiotics, giving antibiotics is not justified as an initial treatment.
For acute maxillary sinusitis, the evidence suggests that antibiotics are effective for
people with radiologically confirmed sinusitis. The reviewers suggest that clinicians
should weigh up the modest benefits (NNTB from 3 to 6) against the potential for
adverse effects.Elsevier Ltd. All rights reserved.
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streptococcal tonsillitis, common cold and acute purulent rhinitis, and acute
maxillary sinusitis seems to be discretionary rather than prohibited or mandatory, at
least for non-severe cases.
& 2004 Elsevier Ltd. All rights reserved.Introduction
A number of issues need to be addressed when
considering the role of antibiotics for upper
respiratory tract infections (sore throat, common
cold, acute and chronic purulent rhinitis, purulent
rhinitis, acute sinusitis and acute otitis media). The
first is the microbiology, as it is not always clear if
an infection is of a viral, bacterial or mixed nature.
The second issue is the need for antibiotics, as most
of the upper respiratory tract infections will
resolve without the need for antibiotics and, in
general, the morbidity is low. However, there is a
small risk of serious complication (e.g. meningitis
with acute otitis media) with all these conditions,
and this in part influences clinicians in their desire
to prescribe antibiotics.2 Patients’ perceived ex-
pectations and other non-clinical factors can
influence the decision to prescribe antibiotics.3
The amount and type of antibiotics prescribed in
different countries varies enormously, and is
unlikely to be caused by differences in frequency
of bacterial infections.4 Cars et al.4 suggest that
prescribing patterns can be influenced by the
attitudes of physicians and patients to antibiotics,
as well as historical backgrounds, cultural and
social factors, and disparities in healthcare sys-
tems. The current concern about antibiotic usage in
primary care is the increase in resistance to
antibiotics,5 and this has led to the examination
of strategies to reduce antibiotic prescribing, such
as multiple educational interventions6 and delayed
prescriptions.7 The aim of this paper is to review
the literature on antibiotics for upper respiratory
tract infections from the Cochrane Library of
systematic reviews. This will include Cochrane
reviews on antibiotics for otitis media, sore throat,
common cold and acute purulent rhinitis, and acute
maxillary sinusitis. It will not review antibiotics for
acute bronchitis, as, by definition, this condition
has some lower respiratory tract component (i.e.
lower respiratory tract signs). In addition, the
studies reviewed here have been criticized for not
systematically excluding acute pneumonia.8
This overview reports the measure of effect
published in the Internet version of the Cochrane
review (URL http://www.cochrane.org/in-
dex2.htm). These include the odds ratio (OR),
relative risk (RR) or absolute risk reduction (ARR).The CD-ROM version of the Cochrane library
enables the reader to choose between an OR or
an RR. Given that Cochrane reviews only contain
randomized trials, the RR should be used, and it is
likely that all reviews will report this in future.
Numbers needed to treat for a benefit (NNTB) and
numbers needed to treat to get a harm (NNTH)
from pooled values have not been used in this
overview, because to do so assumes a control event
rate, which is problematic for the common cold.
The control event rate for persisting symptoms for
the common cold range from 5–66%, so it is difficult
to chose an appropriate control event rate. This is a
controversial area, and it is probably safer to report
the rates for the statistically significant studies, as
they may reflect the true control event rate more
closely.Antibiotics for acute otitis media
The Cochrane review on antibiotics for acute otitis
media in children included eight randomized-
controlled trials with patient-relevant outcomes.9
Antibiotic usage for acute otitis media varies from
31% in the Netherlands to 98% in the USA.9 All of the
trials were from developed countries, and the
quality of studies was generally high. Pain was not
significantly reduced in the first 24 h but, for days
2–7, RRR in pain was 30% (95% confidence intervals
[95% CI] 19–40%). This translates to an ARR of 7%,
meaning that about 15 children needed to be
treated to prevent one child having pain for days
2–7. For hearing outcomes, no clinically or statis-
tically significant difference in tympanometry
results were reported at 1 or 3 months after the
acute episode, suggesting no effect on hearing.
However, audiometry was carried out in only two
studies and incompletely reported. van Buchem et
al.10 reported that 31% of the patients showed an
air/bone gap of more than 20 dB after 1 month.
After 2 months, this was still the case in 19% of
patients. Here again, no significant differences
were observed between the groups, although a
reduction in contralateral otitis media was found in
the antibiotic group. However, results were hetero-
geneous, and this was non-significant in the
random-effects model. Adverse effects, such as
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for the one statistically significant study was 6. The
OR for the increase in adverse effects was 1.94 (95%
CI 1.28–2.94). The authors found few serious
complications in the group treated with antibiotics
compared with the control group. In just over 2000
children studied, only one case of mastoiditis
occurred (in a group treated with penicillin).11
Hence, the applicability of these findings to groups
in whom mastoiditis is common is uncertain. One of
the excluded studies (open, semi-randomized study
conducted in Sweden in 1954)12 reported high rates
of mastoiditis. Patients were randomized by case-
sheet number, but a proportion (about 30 out of
220) requested, and were granted, entry to the
penicillin group. The rate of mastoiditis was 17% in
the untreated group compared with 1.5% in the
sulphonamide group, and 0% in the penicillin-
treated group. The biases of this study (semi-
randomization and unblinded outcome assessment)
are unlikely to explain such a large difference.11,12
Most trials used 7 days of antibiotic treatment.
Another systematic review compared 5 days with
8–10 days of antibiotics, and showed a further
modest reduction with longer treatment, but with
an NNTB of 44 at 20–30 days.13
Some clinical predictors could dictate different
management approaches. The key factors are age,
fever and the presence of vomiting. Burke et al.14
and Appelman et al.15 both found higher rates of
failure of placebo treatment among younger people
(less than 2 years), and people with bilateral acute
otitis media, but the differences were modest.
Little et al.16 found that a subgroup of patients
with temperatures over 37.5 1C, and who were
vomiting, were more likely to benefit from anti-
biotics (oral antibiotics even though they were
vomiting). A study of delayed prescription by Little
et al.17 may have greatly influenced the non-
antibiotic management of acute otitis media. A
relative risk reduction of 75% was found in the use
of antibiotics, despite the delayed group having
significantly more fever and pain. This approach has
been reflected in recent USA guidelines on the use
of antibiotics for acute otitis media. The guidelines
recommend antibiotics for children younger than 6
months of age (excluded in the study by Little et al.
study17). Observation is sanctioned if the diagnosis
is unclear and the illness is not severe in infants
aged 6–24 months, and for non-severe illness in
children 2 years and over.18
The authors of the Cochrane reviews concluded
that antibiotics shorten the course of acute otitis
media. However, in the West, most cases sponta-
neously remit with no complications, and the NNTB
is about 15. Therefore, management should em-phasize advice about adequate analgesia and the
limited role for antibiotics. Cates19 has developed
an appropriate handout, and tested this together
with an optional antibiotic prescription. The hand-
out is available at URL http://www.nntonline.netAntibiotics for sore throat
The authors of the Cochrane review on antibiotics
for throat reviewed 26 randomized-controlled trials
covering 12,669 cases of sore throat.20 Sixteen
studies did not distinguish between bacterial and
viral cause; however, eight studies included a group
of patients who were A beta haemolytic strepto-
cocci (GABHS)-positive only, whereas two studies
excluded patients who were GABHS-positive.
Non-suppurative complications
Only 10 studies (two cases in the control group)
reported acute glomerulonephritis as an end point.
The 95% confidence interval was wide (OR ¼ 0.07;
95% CI 0.00–1.32), which precludes the claim that
antibiotics protect sore throat sufferers from acute
glomerulonephritis. A number of studies found that
antibiotics reduced acute rheumatic fever to about
a third of that in the placebo group (OR ¼ 0.30; 95%
CI 0.20–0.45). Two studies reporting a significant
reduction in rheumatic fever used intramuscular
antibiotics.21,22 Rheumatic fever only occurred as
an outcome before 1961, so it is difficult to know
whether there is still a benefit in developed
countries. The Cochrane reviewers refer to Abori-
ginal communities in Australia, who they believe
would be an at-risk group in a developed country.
The same would apply to Maori and Pacific Island
people living in New Zealand.23
Suppurative complications
The incidence of acute otitis media reduced by
about a quarter when antibiotics were given for
sore throat (OR ¼ 0.22; 95% CI 0.11–0.43) (the
NNTBs for the two statistically significant studies
were 21 and 25), and the incidence of acute
sinusitis reduced to half of that in the placebo
group (OR ¼ 0.46; 95% CI 0.10–2.05). Of the eight
studies reporting these outcomes, only one was
statistically significant; NNTB ¼ 43. Data indicate
that the incidence of quinsy was also reduced
compared with the placebo group (OR ¼ 0.16; 95%
CI 0.07–0.35). Of the three studies that were
statistically significant for reduction in quinsy, the
NNTBs ranged from 20 to 55 people treated to
prevent one case of quinsy.
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At 3 days, antibiotics reduced symptoms of sore
throat (OR ¼ 0.41; 95% CI 0.36–0.48), headache
(OR ¼ 0.70; 95% CI 0.52–0.94) and fever
(OR ¼ 0.62; 95% CI 0.46–0.85). Findings were
statistically significant in 11 out of 14 studies of
sore throat, two out of seven for fever and two out
of three for headache. The NNTBs to reduce
symptoms of sore throat for the statistically
significant studies ranged from 2 to 7. The effec-
tiveness of antibiotics was increased in participants
with streptococci reported on throat culture. Few
children (o13 years of age) were included in these
studies, and only 61 were available for assessment
of symptoms at day 3.1950s to 1960s and thereafter
For every 100 patients treated with antibiotics
rather than placebo in these trials (conducted
mostly during the 1950s), the Cochrane reviewers
estimated that there was one less case of acute
rheumatic fever, two less cases of acute otitis
media, and three less cases of quinsy. These need
to take in to account possible changes in the
condition. For example, the complication rate of
acute otitis media among people with sore throats
before 1975 was 3%. An NNTB of about 50 to
prevent one case of acute otitis media can be
estimated from the data. After 1975, this compli-
cation rate fell to 0.7%, and, applying the odds of
reducing the complication with antibiotics from the
data table, yields an NNTB of nearly 200 to prevent
one case of acute otitis media. The reviewers
recommend that these factors need to be taken
into account in considering antibiotic treatment.
They go on to balance risks with benefits in
developing countries: ‘‘in other parts of the world
the incidence of acute rheumatic fever is so low
(one estimate is that it took 12 general practi-
tioners’ working lifetimes to encounter one new
case of acute rheumatic fever in Western Scotland
in the 1980s)24 that the risks of serious complica-
tion arising from using antibiotics for this complica-
tion might be of the same order as that of acute
rheumatic fever.’’ They estimate the NNTB to be
about 3.5 for those with a positive throat swab for
streptococcus and 5.5 for those with a negative
swab. This translates to about 16 h of improvement
in people given antibiotics compared with those
given placebo. The reviewers correctly conclude
that ‘‘use of antibiotics appears to be discretionary
rather than prohibited or mandatory.’’ The debate
continues, however, as the guidelines from theInfectious Disease Society of America (2002) re-
commend routine treatment.1Antibiotics for the common cold and
acute purulent rhinitis
The Cochrane review on antibiotics for the common
cold and acute purulent rhinitis reviewed nine trials
involving 2249 (2157 analysed) people aged be-
tween 2 months and 79 years (some trials had no
upper age limit).25 When pooled, the relevant
studies for the common cold had a non-significant
improvement of OR 0.8, 95% CI (0.59–1.08) with
antibiotics. For acute purulent rhinitis, the OR was
0.47, 95% CI (0.26–0.85) (Arroll B, personal commu-
nication, 2004). One study found a benefit from
amoxicillin with clavulanate for the 20% of patients
with positive nasopharyngeal swabs (but did not
have purulent rhinitis necessarily) for Haemophilus
influenzae, Moraxella catarrhalis and Streptococcus
pneumoniae. The magnitude of effect for this study
was a benefit of 1 day for that 20% of patients. Only
three studies involving adults reported adverse
effects (usually gastrointestinal) and, when pooled,
the OR was 3.6, 95% CI 2.21–5.89; NNTH 5–25. Only
two studies of children reported adverse effects,
and this was not significant when pooled.
These findings are consistent with guidelines for
non-specific upper respiratory infections for the
common cold, which recommend no antibiotics in
the first instance.26 The issue of acute purulent
rhinitis is more problematic, as the previous
guidelines have stated that antibiotics are not
effective for acute purulent rhinitis, a finding based
on the results of only one study.27 Ironically, this is
the only study not to show a benefit for antibiotics,
which may be due to chance or because it is the
only study to use a cephalosporin. The other studies
used amoxil, co-trimoxazole or tetracycline, and
the NNTBs for those studies ranged from 6 to 8.28 To
add to this contradiction over antibiotics for acute
purulent rhinitis, a Cochrane review on chronic
purulent (persistent 410 days) rhinitis found a
benefit from antibiotics.29 This does not mean that
all cases of acute purulent rhinitis require anti-
biotics, because most people will improve without
antibiotics, but it may be reasonable to give them
antibiotics when resolution is delayed.Antibiotics for acute maxillary sinusitis
The Cochrane review for antibiotics for acute
maxillary sinusitis reviewed 49 trials with 13,660
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maxillary sinus and not other sinuses in the head.
Only studies with radiological evidence for acute
maxillary sinusitis were included. A beneit was
found for amoxil 500mg three times daily for 10
days and amoxil 750mg three times daily for 7 days
(RR ¼ 2.24, 95% CI 1.4–3.6; NNTB for the one
significant study ¼ 3). They also found penicillin to
be effective compared with placebo at either
400mg three times daily or 1320mg three times
daily for 10 days (RR ¼ 2.22; 95% CI 1.09–4.51; NNTB
for the one significant study ¼ 6). Two studies
conducted in primary care, where a clinical rather
than a radiological diagnosis was made, found no
benefit for antibiotics.31,32 One of these studies
included patients with symptoms and an elevated c-
reactive protein or erythrocyte sedimentation rate,
and found a benefit in pain reduction at day 3, but
no difference in cure. More patients in the penicillin
group were completely free of pain compared with
placebo at the end of the study, but this was only in
the group with higher baseline pain scores. Compar-
isons between classes showed no significant benefit
when the newer non-penicillins were compared with
penicillins. These newer non-penicillins included
clarithromycin, azithromycin, cefixime, minocycline
and erythromycin. Compared with amoxicillin-cla-
vulanate, no benefit was found from the newer non-
penicillins, such as clarithromycin, azithromycin,
levofloxacin and second/third generation cephalos-
porins. Drop-out rates for cephalosporin/macrolide
antibiotics were lower compared with amoxicillin-
clavulanate (RR ¼ 0.47, 95% CI 0.3–0.73). The
reviewers concluded that, for acute maxillary
sinusitis confirmed radiographically or by aspiration,
current evidence is limited, but supports the use of
penicillin or amoxicillin for 7–14 days. They suggest
that clinicians should weigh the moderate benefits
of antibiotic treatment against the potential for
adverse effects. Recent guidelines are slightly more
cautious and recommend symptomatic treatment
and reassurance as the preferred initial manage-
ment strategy for patients with mild symptoms, and
that antibiotic therapy should be reserved for
people with moderately severe symptoms who meet
the criteria for the clinical diagnosis of acute
bacterial rhinosinusitis and for people with severe
symptoms.33Conclusions
The four Cochrane reviews reveal a limited role for
antibiotics in the four upper respiratory tract
infections discussed above. Other than for radi-
ologically proven acute maxillary sinusitis, thereviewers do not recommend antibiotics as a first-
choice treatment for any of the four conditions.
Guidelines tend to reflect the level and type of
evidence that a group will accept, and this may
explain why the guidelines from the Infectious
Disease Society of America (2002) recommend
routine treatment for otitis media, whereas the
Cochrane reviewers are more cautious. There has
long been a consensus about the lack of need for
antibiotics and, even with the new information on
acute purulent rhinitis (along with a common cold),
the reviewers remain consistent with the older
guidelines in not recommending antibiotics as a
first-line treatment.
There is a global need to reduce antibiotic usage
and, as most antibiotics are used in primary care,
this is where the reduction needs to take place. The
role of systematic reviews is to provide the best
summary of the evidence to date. Hopefully,
guideline groups will take heed of Cochrane re-
views. The research on delayed prescriptions has
given clinicians the confidence to broach the issue
of ‘no initial antibiotics’, especially for acute otitis
media. This needs to be tempered with the need to
provide easy access to reassessment for patients,
and the need to monitor the population for changes
in serious complications such as mastoiditis. Finally,
we need to be mindful of changes in resistance
patterns. Evidence from Sweden and New Zealand
has shown that a reduction in antibiotic use can be
accompanied by a reduction in antibiotic resis-
tance.34,35 The opposite may also be the case
where increases in resistance occur. Perhaps, a
time will come when antibiotics are only occasion-
ally used for upper respiratory infections in primary
care, and their use will be mainly in placebo-
controlled trials to determine if there are any
major changes in efficacy.
Practice points Routine antibiotics for the four aspects of acute
upper respiratory tract infection are not man-
dated for non-severe cases. Antibiotics for acute otitis media are effective
but the NNTB is about 15. Delayed prescriptions for antibiotics for acute
otitis media may be a good compromise for not
giving immediate antibiotics. Antibiotics may not be necessary for sore throat
in areas where rheumatic fever and glomerulo-
nephritis are uncommon. Antibiotics are not effective for the common
cold. Antibiotics may be effective for acute purulent
rhinitis associated with the common cold, but
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will get better without antibiotics. Antibiotics for acute maxillary sinusitis (radio-
graphically proven) are effective with a NNTB of
about 6. Routine antibiotics for non-severe cases
may not be warranted.
Research directions Monitoring of complications will be needed if
policies of reduced antibiotic use are to be
recommended for upper respiratory tract infec-
tions. This should include monitoring for mastoi-
ditis, pneumonia, rheumatic fever, glomerulo-
nephritis and admissions for complications of
acute maxillary sinusitis. A closely supervised process may be needed in
high-risk populations. Monitoring the microbiol-
ogy needs to be ongoing in order to determine if
new organisms are involved and if there are
major shifts in resistance. Comparisons of antibiotics with symptomatic
treatment would be helpful for some of the
above conditions.References
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